New trial
Phase II Study of Talquetamab (GPRC5D/CD3 Bispecific) in Post-Transplant Multiple Myeloma Maintenance
- Trial ID
- NCT06461988 on ClinicalTrials.gov
- Cancer type
- Multiple Myeloma
- Published in
- New in Oncology - June 6, 2025
Stanford University is launching an open-label, non-randomized Phase II study evaluating talquetamab—a bispecific antibody targeting GPRC5D and CD3—as monotherapy in cycle 1 and in combination with lenalidomide from cycles 2-13 for symptomatic multiple myeloma post stem cell transplant.
More in multiple myeloma
-
Trial result · Oct 22, 2026 · NCT04184050
MK-4002 (BCMA×CD3 trispecific T-cell engager) drives 63% ORR at 12 mg in heavily pretreated RRMM -
Trial result · Oct 15, 2026 · NCT04557150
Forimtamig (GPRC5D×CD3 2:1 bispecific) posts 72% ORR at optimized SC dosing—but toxicity caps escalation in RRMM -
New trial · Oct 15, 2026 · NCT06948084
Phase 2 daratumumab plus teclistamab is compared with DPd or DKd in high-risk, second-line multiple myeloma -
Trial result · Oct 1, 2026 · NCT03301220
Daratumumab (anti-CD38) cuts progression risk in Japanese high-risk SMM vs monitoring (AQUILA) -
Trial result · Sep 24, 2026 · NCT05469893
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma